Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2016 Jan 15

PMID 26764252

Citations 42

Authors

Oliver Konigsbrugge

Florian Posch

Julia Riedl

Eva-Maria Reitter

Christoph Zielinski

Ingrid Pabinger

Cihan Ay

Affiliations

Soon will be listed here.

Abstract

Background: In cancer patients, reduced serum albumin has been described as a marker for global declining health and poor prognosis. Our aim was to investigate the association of albumin concentrations with the occurrence of venous thromboembolism (VTE) and mortality in patients with cancer.

Methods: This investigation was performed in the framework of the Vienna Cancer and Thrombosis Study (CATS), a prospective observational cohort study. We included 1,070 patients with active cancer and assayed serum albumin from venous blood taken at study inclusion. Risk for occurrence of VTE was calculated in a proportional subdistribution hazard regression model with respect to competing risk of death and adjusted for cancer site, leukocyte count, estimated glomerular filtration rate, and cholinesterase.

Results: Patients (630 males [58.9%] and 440 females [41.1%]) were observed for a median of 723 days. During follow-up, 90 VTE events (8.4%) and 396 deaths (37.0%) occurred. The median albumin was 41.3 g/L (25th-75th percentile, 37.6-44.2). Patients with albumin levels below the 75th percentile had a 2.2-fold increased risk of VTE (95% confidence interval [CI] 1.09-4.32), as well as a 2.3-fold increased risk of death (95% CI 1.68-3.20) compared with patients with albumin above the 75th percentile.

Conclusion: Decreased serum albumin levels in cancer patients were significantly associated with increased risk of VTE and mortality. Serum albumin, a marker of a cancer patient's overall prognosis, could be considered for risk assessment of important clinical outcomes such as VTE and mortality.

Implications For Practice: Cancer patients are at increased risk of venous thromboembolism (VTE). In this prospective cohort study of 1,070 cancer patients, decreased serum albumin was a marker for risk of VTE and mortality, independent of kidney or liver function and inflammation markers. The study identified a group of patients with high risk of cancer-associated VTE and a reduced prognosis who may benefit from supportive therapy such as primary VTE prophylaxis.

Citing Articles

Machine learning algorithms able to predict the prognosis of gastric cancer patients treated with immune checkpoint inhibitors.

Li H, Zhu Z, Sun Y, Yuan C, Wang M, Wang N World J Gastroenterol. 2024; 30(40):4354-4366.

PMID: 39494097 PMC: 11525865. DOI: 10.3748/wjg.v30.i40.4354.

External Validation of Risk Scores for Predicting Venous Thromboembolism in Ambulatory Patients with Lung Cancer.

Yan A, Yip D, Peterson G, Samarawickrema I, Naunton M, Newman P Cancers (Basel). 2024; 16(18).

PMID: 39335138 PMC: 11430721. DOI: 10.3390/cancers16183165.

Serum albumin, genetic susceptibility, and risk of venous thromboembolism.

Sun Y, Deng J, Ding Y, Luo S, Li S, Guan Y Res Pract Thromb Haemost. 2024; 8(5):102509.

PMID: 39221449 PMC: 11364004. DOI: 10.1016/j.rpth.2024.102509.

The association between lactate dehydrogenase to serum albumin ratio and in-hospital mortality in patients with pulmonary embolism: a retrospective analysis of the MIMIC-IV database.

Hu J, Zhou Y Front Cardiovasc Med. 2024; 11:1398614.

PMID: 38962086 PMC: 11220285. DOI: 10.3389/fcvm.2024.1398614.

Association between inflammation-based prognostic markers and mortality after hip replacement.

Oh A, Kwon J, Jin G, Kong S, Lee D, Park J Sci Rep. 2024; 14(1):9263.

PMID: 38649407 PMC: 11035583. DOI: 10.1038/s41598-024-58646-y.

References

Moller Pedersen L, Sorensen P . Mediators of inflammation correlate with microalbuminuria in patients with non-Hodgkin's lymphoma. Br J Haematol. 2003; 121(2):275-9. DOI: 10.1046/j.1365-2141.2003.04285.x. View

Proctor M, McMillan D, Horgan P, Fletcher C, Talwar D, Morrison D . Systemic inflammation predicts all-cause mortality: a glasgow inflammation outcome study. PLoS One. 2015; 10(3):e0116206. PMC: 4346265. DOI: 10.1371/journal.pone.0116206. View

Khorana A, Kuderer N, Culakova E, Lyman G, Francis C . Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10):4902-7. PMC: 2384124. DOI: 10.1182/blood-2007-10-116327. View

Folsom A, Lutsey P, Heckbert S, Cushman M . Serum albumin and risk of venous thromboembolism. Thromb Haemost. 2010; 104(1):100-4. PMC: 2902783. DOI: 10.1160/TH09-12-0856. View

Shah M, Capanu M, Soff G, Asmis T, Kelsen D . Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost. 2010; 8(8):1702-9. DOI: 10.1111/j.1538-7836.2010.03948.x. View

Kanz R, Vukovich T, Vormittag R, Dunkler D, Ay C, Thaler J . Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost. 2010; 9(1):57-63. DOI: 10.1111/j.1538-7836.2010.04069.x. View

Yi J, Lee J, Park S, Lee K, Lee J, Lee K . A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Oncology. 2011; 80(3-4):175-80. DOI: 10.1159/000328449. View

Asher V, Lee J, Bali A . Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. Med Oncol. 2011; 29(3):2005-9. DOI: 10.1007/s12032-011-0019-5. View

Mahmoodi B, Gansevoort R, Naess I, Lutsey P, Braekkan S, Veeger N . Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts. Circulation. 2012; 126(16):1964-71. PMC: 3520022. DOI: 10.1161/CIRCULATIONAHA.112.113944. View

10.

Seebacher V, Grimm C, Reinthaller A, Heinze G, Tempfer C, Hefler L . The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 2013; 171(1):101-6. DOI: 10.1016/j.ejogrb.2013.07.044. View

11.

Ayuk F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C . Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation. Ann Hematol. 2013; 93(5):855-61. DOI: 10.1007/s00277-013-1957-0. View

12.

Du X, Tang L, Mao Y, Sun Y, Zeng M, Kang T . The pretreatment albumin to globulin ratio has predictive value for long-term mortality in nasopharyngeal carcinoma. PLoS One. 2014; 9(4):e94473. PMC: 3981820. DOI: 10.1371/journal.pone.0094473. View

13.

Douglas E, McMillan D . Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. Cancer Treat Rev. 2013; 40(6):685-91. DOI: 10.1016/j.ctrv.2013.11.007. View

14.

Pant S, Martin L, Geyer S, Wei L, Van Loon K, Sommovilla N . Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014; 120(12):1780-6. PMC: 4265390. DOI: 10.1002/cncr.28648. View

15.

Konigsbrugge O, Lotsch F, Zielinski C, Pabinger I, Ay C . Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. Thromb Res. 2014; 134(1):44-9. DOI: 10.1016/j.thromres.2014.04.002. View

16.

Ulas A, Turkoz F, Silay K, Tokluoglu S, Avci N, Oksuzoglu B . A laboratory prognostic index model for patients with advanced non-small cell lung cancer. PLoS One. 2014; 9(12):e114471. PMC: 4256446. DOI: 10.1371/journal.pone.0114471. View

17.

Olson N, Cushman M, Lutsey P, McClure L, Judd S, Tracy R . Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. J Thromb Haemost. 2014; 12(12):1993-2001. PMC: 4643856. DOI: 10.1111/jth.12742. View

18.

Lyman G, Bohlke K, Khorana A, Kuderer N, Lee A, Arcelus J . Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015; 33(6):654-6. PMC: 4881372. DOI: 10.1200/JCO.2014.59.7351. View

19.

Schemper M, Smith T . A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17(4):343-6. DOI: 10.1016/0197-2456(96)00075-x. View